Sharechat Logo

Importing still difficult says Ebos

By Phil Boeyen, ShareChat Business News Editor

Thursday 22nd February 2001

Text too small?
Medical distributor Ebos Group (NZSE: EBO) is struggling with currency fluctuations which it says are to blame for a merely credible result in its half-year profit.

For the six months ended December Ebos profit rose just 5% on the previous year to $1.956 million, despite sales increasing to $50.4 million from $34 million in 1999.

"The overall result is best described as credible in a climate presently unfavourable to importers," the company said in a statement.

Ebos says margin impact of ongoing weakness in New Zealand and Australian currencies continues to be the greatest influence on profitability and has neutralised the very positive impact of the group's growth initiatives.

Although New Zealand operating divisions and the Richard Thomson subsidiary in Australia reached profit targets, the company's Australian orthopaedic subsidiary returned only a breakeven performance compared with a profit the previous half year.

Ebos says its directors and senior executives continue to work on a range of growth opportunities, particularly those that add brand security or add value to existing business units.

The company is planning a 6.5 cents per share dividend, fully imputed.

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Ebos still hungry for acquisitions after $1.1 bln Symbion deal, Waller says
Ebos meets prospectus forecast with 5.5 percent gain in FY profit
Ebos shareholders approve $1.1 billion purchase of Symbion
Ebos grabs scale with $1.1 bln purchase of Aussie pharma distributor Symbion
Ebos kicks tyres on potential acquisitions
Ebos lifts profit by 19%, targets growth in animal health
Ebos funding line smaller than previously flagged at $135 mln
Ebos Group
Ebos backs off British purchase, evaluates "significant" Australasian asset
Ebos reports higher profit, looks for acquisitions